Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05898841
Other study ID # GESIDA 12422
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date May 26, 2023
Est. completion date April 1, 2025

Study information

Verified date June 2023
Source Fundacion SEIMC-GESIDA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression and/or reduction of fatty metabolic liver disease, attenuating inflammation and liver fibrosis.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 75
Est. completion date April 1, 2025
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients over 18 years of age with HIV infection who have never received antiretroviral treatment with Rilpivirine. - Have a stable ART pattern for at least the last 6 month Exclusion Criteria: - Not having received more than three previous lines of antiretroviral treatment - No resistance mutations that compromise the efficacy of Rilpivirine, Dolutegravir, Tenofovir (TDF and/or TAF) or Emtricitabine. - Have an HIV viral load < 50 copies/ml for at least the last 6 months, 1 blip below 500 copies/ml is allowed during this period. - Have an ultrasound-diagnosed fatty liver metabolic disease or a CAP (Controlled Attenuation Parameter®) measurement > 238 dB/m with an IQR < 30 dB/m. - Have an fatty liver metabolic disease with some degree of fibrosis diagnosed by ET (Fibroscan®) > 5.2 kPa. In patients in whom ET is not possible, have a FIB-4 >1.3. - Be able to understand and comply with the requirements and instructions of the protocol. - Understanding long-term commitment to study - Acceptance of their participation in the study by signing an informed consent form. Exclusion Criteria: - Have chronic HBV infection (presence of HBsAg+) or HCV (detectable HCV viral load). Patients with past treated HCV are also not allowed to be included (does not include patients with spontaneously resolved HCV infection). - Have diabetes mellitus on treatment with SGLT2, GLP1 or plioglitazone of less than 6 months duration. - Have a history of alcohol abuse - Harmful alcohol consumption, defined as >30 grams of alcohol per day in men and >20 grams of alcohol per day in women. - Have chronic decompensated liver disease, defined as any of the following: presence of encephalopathy, ascites, coagulopathy, oesophageal or gastric varices, or persistent jaundice. - Any previous physical or mental condition (such as habitual drug use) that the investigator believes may interfere with the patient's ability to comply with the study protocol. - Pregnancy or breastfeeding at the screening visit or at any time during the study or intention to become pregnant during the study period. - Prior history of Rilpivirine use of any duration.

Study Design


Intervention

Drug:
Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day
DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.
Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day
TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.
Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.

Locations

Country Name City State
Spain Hospital Universitario Gregorio Marañon Madrid
Spain Hospital universitario Infanta Leonor Madrid
Spain Hospital Universitario Infanta Sofía Madrid
Spain Hospital Universitario La Paz Madrid

Sponsors (1)

Lead Sponsor Collaborator
Fundacion SEIMC-GESIDA

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the efficacy of Rilpivirine (RPV) as part of the antiretroviral treatment regimen in VIH-infected people, to slow the progression and/or reduce liver fibrosis of any degree To measure the no progression and/or regression of liver fibrosis:
No change in liver stiffness as measured by ET (Transient Elastography) or FIB4 at the 18-month visit with respect to the baseline, the intervention group (branches 1 and 2) compared to the control group.
18 months
Primary To evaluate the efficacy of Rilpivirine (RPV) as part of the antiretroviral treatment regimen in VIH-infected people, to slow the progression and/or reduce liver fibrosis of any degree Reduction in liver stiffness measured by ET or FIB4 at the 18-month visit from baseline in the intervention group (arms 1 and 2) versus the control group. 18 months
Secondary Efficacy of RPV in reducing liver fibrosis of any grade To evaluate the efficacy of RPV in reducing liver fibrosis of any grade, as measured by non-invasive tests, in HIV-infected people:
as part of a nucleoside analogue-free antiretroviral treatment regimen
as part of an antiretroviral treatment regimen that includes tenofovir
Proportion of subjects with ET measurement < 5.2 kPa in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months from the start of treatment.
12-18 months
Secondary Efficacy of RPV in reducing liver fibrosis of any grade Proportion of subjects with a FIB4 measurement < 1.3 in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months from the start of treatment. 12-18 months
Secondary Efficacy of RPV in reducing liver fibrosis of any grade The mean reduction in the APRI measure in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months after the start of treatment. 12-18 months
Secondary Efficacy of RPV in reducing liver fibrosis of any grade Proportion of subjects with an APRI measure < 0.5 in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months from the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis The mean reduction in the percentage of liver fat, measured by magnetic resonance imaging, which measures the proton density fraction of fat (MRI-PDFF), between the beginning and the end of the study comparing the intervention group (arms 1 and 2) vs control group 18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis Difference in the proportion of responders between the intervention group (arms 1 and 2) at 18 months from the start of treatment, defined as those who achieve >30% reduction in hepatic steatosis measured by MRI-PDFF 18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis Proportion of subjects with hepatic steatosis measured as MRI-PDFF > 5% steatosis in the intervention group (arms 1 and 2) compared to the control group at 18 months from the start of treatment 18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis The mean reduction of the CAP measurement in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis The mean reduction in the FLI measurement in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis The mean reduction in the HSI measure in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months from the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis The mean reduction of the TyG measurement in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis Proportion of subjects with hepatic steatosis measured as CAP > 238 dB/m in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months from the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis The mean reduction in the FLI measurement in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis Proportion of subjects with hepatic steatosis measured as HSI score > 36 in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months from the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to reduce hepatic steatosis Proportion of subjects with hepatic steatosis measured as TyG score > 8.38 in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months from the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the insulin resistance The mean reduction of the HOMA-IR value in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the insulin resistance Difference in the proportion of subjects with insulin resistance, measured as HOMA-IR >2.5 in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months after the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the insulin resistance Mean reduction in TyG (IR) measurement in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months from the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the insulin resistance Difference in the proportion of subjects with insulin resistance measured as TyG > 4.68 in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months from the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the insulin resistance The mean reduction in fasting blood glucose (mg/dL) in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months from the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the insulin resistance Difference in the proportion of subjects with fasting glycemia > 100 mg/dL in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the insulin resistance The reduction in the measurement of abdominal circumference and waist ratio/in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatmen 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism The mean reduction in fasting triglycerides (mg/dL) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism Difference in the proportion of subjects with hypertriglyceridemia (value > 150 mg/dL) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism Mean reduction in fasting LDL cholesterol quantification (mg/dL) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism Difference in the proportion of subjects with elevated LDL cholesterol (value > 130 mg/dL and value >100 mg/dL) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months of start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism The mean increase in fasting HDL cholesterol quantification (mg/dL) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism Difference in the proportion of subjects with elevated HDL cholesterol (value > 45 mg/dL in men and value > 50 mg/dL in women) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months from the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism The mean reduction in fasting non-LDL cholesterol quantification (mg/dL) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment. 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to improve the lipid metabolism Difference in the proportion of subjects with elevated non-LDL cholesterol (value > 160 mg/dL) in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months after the start of treatment 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the liver inflammation The mean change in ALT value (IU/mL) in the intervention group (arms 1 and 2) vs. the control group at 12 and 18 months from baseline 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the liver inflammation The mean change in AST value (IU/mL) in the intervention group (arms 1 and 2) versus the control group at 12 and 18 months from the baseline visit 12-18 months
Secondary To evaluate the efficacy of Rilpivirine (RPV) to decrease the liver inflammation. The change of the gene expression value of: IL1-beta, IL6, IL10, MCP1, PAI-1, TGF-alpha, TNF-alpha in PBMCs in the intervention group (arms 1 and 2) compared to the control group at 12 and 18 months compared to the baseline visit. 12-18 months
Secondary Efficacy of RPV to reduce hepatic steatosis/fibrosis. To assess the efficacy of RPV as part of the antiretroviral treatment regimen in HIV-infected individuals to reduce hepatic steatosis/fibrosis based on the presence of PNPLA3 and MBOAT7-TMC4 genetic polymorphisms. 18 months
Secondary To characterise the effects of RPV on the expression of inflammatory and fibrogenic markers in peripheral blood mononuclear cells . Analyse the gene expression of inflammatory and fibrogenic markers in peripheral blood polymorphonuclear cells by RT-PCR: IL1-gamma, IL6, IL10, MCP1, P AI-1, TGF-beta, TNF-alpha. 18 months
Secondary To characterise the effects of RPV on the expression of inflammatory and fibrogenic markers in peripheral blood mononuclear cells . Measurement of ALT, AST and GGT in plasma as markers of inflammation. 18 months
Secondary Efficacy of RPV to reduce the progression to steatohepatitis In previous studies it has shown that PNPLA3, TM6SF2, and MBOAT7-TMC4 polymorphisms are associated with elevated ALT levels and histologic parameters of nonalcoholic steatohepatitis and fibrosis severity.
On the baseline visit will be collected biological samples for genetuic study. A 3 ml blood sample will be drawn into an EDTA tube at baseline visit for determination of PNPLA3 (C, G alleles) and MBOAT7-TMC4 (G, A alleles) genetic polymorphisms.
18 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2